Explore p-Tau 205 and p-Tau 212: Emerging Biomarkers for Alzheimer’s Disease Research
On-Demand Recording
Speakers:
Thomas K Karikari, PhD, Assistant Professor of Psychiatry, University of Pittsburgh
Wesley Straub, Vice President of Product Management, Quanterix
Explore the scientific rationale and clinical relevance of p-Tau 205 and p-Tau 212, two emerging biomarkers showing promise for improving early detection and disease staging.
This on-demand webinar showcases how p-Tau 205 and p-Tau 212 may offer complementary insights to established markers like p-Tau 181 and p-Tau 217—and help move the field closer to scalable, blood-based Alzheimer’s diagnostics.
Watch the webinar to learn:
- The biological relevance and phosphorylation dynamics of p-Tau 205 and p-Tau 212 in the context of Alzheimer’s pathology
- How these markers compare with and complement existing p-Tau biomarkers such as p-Tau 181 and p-Tau 217
- New data on ultra-sensitive detection of p-Tau 205 and p-Tau 212
- Insights into the potential clinical utility of p-Tau 205 and p-Tau 212 in early diagnosis, disease staging and differentiation from other dementias
- The future of blood-based biomarkers in Alzheimer’s disease
Fill out the form to access the replay.